Datta A K, Campbell S, Deval B, Nargund G
CREATE Fertility, 150 Cheapside, St Pauls, London EC2V 6ET, United Kingdom.
Facts Views Vis Obgyn. 2015 Dec 28;7(4):241-250.
A series of new technologies and adjuvant therapies have been advocated in order to improve the success of IVF treatment. Dehydro-epiandrostenedione, growth hormones, Coenzyme Q 10, calcium ionosphores, immune therapy, heparin, low-dose aspirin, and vasodilators are among commonly prescribed pharmacological adjuvants. New technologies that are proposed to improve IVF outcomes include advanced sperm selection procedures, time- lapse embryo monitoring, preimplantation genetic screening, assisted hatching endometrial injury or embryo-glue. This review looked into current evidence to justify the use of these co-interventions and whether some of them can still be offered while awaiting more robust evidence to con rm or refute their role.
为了提高体外受精（IVF）治疗的成功率，人们提倡一系列新技术和辅助疗法。脱氢表雄酮、生长激素、辅酶Q10、钙离子载体、免疫疗法、肝素、低剂量阿司匹林和血管扩张剂是常用的药物辅助剂。旨在改善IVF结果的新技术包括先进的精子筛选程序、延时胚胎监测、植入前基因筛查、辅助孵化、子宫内膜损伤或胚胎胶。本综述研究了当前的证据，以证明这些联合干预措施的使用合理性，以及在等待更有力的证据来证实或反驳它们的作用时，其中一些措施是否仍可提供。
